Department of Gastrointestinal Surgery, Zhejiang International Scientific and Technological Cooperation Base of Translational Cancer Research, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Research Center of Basic Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Adv Sci (Weinh). 2024 May;11(18):e2309984. doi: 10.1002/advs.202309984. Epub 2024 Mar 2.
The induction of cuproptosis, a recently identified form of copper-dependent immunogenic cell death, is a promising approach for antitumor therapy. However, sufficient accumulation of intracellular copper ions (Cu) in tumor cells is essential for inducing cuproptosis. Herein, an intelligent cuproptosis-inducing nanosystem is constructed by encapsulating copper oxide (CuO) nanoparticles with the copper ionophore elesclomol (ES). After uptake by tumor cells, ES@CuO is degraded to release Cu and ES to synergistically trigger cuproptosis, thereby significantly inhibiting the tumor growth of murine B16 melanoma cells. Moreover, ES@CuO further promoted cuproptosis-mediated immune responses and reprogrammed the immunosuppressive tumor microenvironment by increasing the number of tumor-infiltrating lymphocytes and secreted inflammatory cytokines. Additionally, combining ES@CuO with programmed cell death-1 (PD-1) immunotherapy substantially increased the antitumor efficacy in murine melanoma. Overall, the findings of this study can lead to the use of a novel strategy for cuproptosis-mediated antitumor therapy, which may enhance the efficacy of immune checkpoint inhibitor therapy.
诱导铜死亡是一种最近发现的铜依赖性免疫原性细胞死亡形式,是一种很有前途的抗肿瘤治疗方法。然而,肿瘤细胞内铜离子(Cu)的充分积累对于诱导铜死亡是必不可少的。在此,通过将氧化铜(CuO)纳米颗粒与铜离子载体依立替康(ES)包封,构建了一种智能铜死亡诱导纳米系统。在被肿瘤细胞摄取后,ES@CuO 被降解以释放 Cu 和 ES,从而协同触发铜死亡,从而显著抑制了小鼠 B16 黑色素瘤细胞的肿瘤生长。此外,ES@CuO 通过增加肿瘤浸润淋巴细胞和分泌的炎症细胞因子进一步促进了铜死亡介导的免疫反应和重塑免疫抑制性肿瘤微环境。此外,将 ES@CuO 与程序性细胞死亡蛋白-1(PD-1)免疫疗法相结合,在小鼠黑色素瘤中显著提高了抗肿瘤疗效。总的来说,本研究的结果可以为铜死亡介导的抗肿瘤治疗提供一种新的策略,可能增强免疫检查点抑制剂治疗的疗效。
Mater Today Bio. 2025-7-29
Front Cell Dev Biol. 2025-7-25
Mediterr J Hematol Infect Dis. 2025-7-1
J Immunother Cancer. 2025-6-8
Immunol Rev. 2024-1
Adv Healthc Mater. 2023-9
Antioxid Redox Signal. 2023-2-2